ReviewAdvances in kidney disease and health2025
Onconephrology.
Review in Advances in kidney disease and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Evolving epidemiology and improving safety of rechallenge in immune checkpoint inhibitor-associated acute kidney injury: an updated meta-analysis.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Subspecialized training in the field of onconephrology offers a uniquely informed approach to the care of the patient with both cancer and kidney disease. There is a significant knowledge gap that has been created by the fact that patients with an estimated glomerular filtration rate <30 mL/min are generally excluded from clinical cancer trials. Thus, oncologists rely on the clinical experience and expertise of onconephrologists to dose cytotoxic chemotherapies, to recognize and manage complications of newer targeted drugs and immunotherapies, to become partners in establishing guidelines relating to the management of these complications, and to collaborate on the design of future clinical trials in this cohort. In this section, we provide a glimpse into some common clinical scenarios encountered by the onconephrologist and demonstrate how clinical data and observations inform decision-making in these situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.